Skip to main content

Listed in IAM Strategy 300 – The World’s Leading IP Strategists, Fang Xie, Ph.D. focuses her practice on establishing, defending, licensing, sharing and monetizing intellectual property rights for life sciences companies. She has broad experience in worldwide patent portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, validity/invalidity analyses, patent infringement evaluations, as well as intellectual property litigation and pre-litigation counseling.

Fang’s primary technical areas include biotechnology, synthetic biology and pharmaceuticals, with a focus on immunotherapy, antibody and biologics/biosimilars, nucleic acid synthesis, gene editing, protein and organism engineering, stem cell technology, biomarkers, diagnostics, small molecule drugs, regenerative medicine, analytical chemistry and cosmetics.

Fang’s typical clients are biopharmaceutical companies at various stages, universities and research institutes, as well as venture capital and institutional investors. Representative clients include a number of venture-backed biopharma startups, a publicly-traded biosynthetic chemistry company, a publicly-traded regenerative medicine company, as well as a number of top tier academic research institutions such as the Whitehead Institute for Biomedical Research, University of Texas Southwestern Medical Center, California Institute of Technology, and the Chinese Academy of Sciences. Fang also frequently works with early-stage biopharmaceutical companies to enhance their IP position and develop licensing and partnership strategies.

Fang’s recent experience includes serving on the litigation team representing a large international pharmaceutical company in a patent infringement action related to certain biomarkers used in drug discovery, as well as investigating a trade secret misappropriation on behalf of a global energy company.

Prior to entering the field of law, Fang conducted her doctoral research at MIT, in the laboratories of Nobel Laureate H. Robert Horvitz and U.S. National Academy of Sciences Member Terry Orr-Weaver. At MIT, she investigated programmed cell death, developmental DNA replication, and gene amplification. She also received post-doctoral training at the Whitehead Institute for Biomedical Research in the areas of genomics, epigenetics, small RNA, and cancer biology. Prior to attending MIT, she had experience studying neuron regeneration and chromosomal evolution.

While at MIT, Fang also assisted a start-up medical device company in managing its patent portfolio, evaluating diagnostic technologies, and drafting patent applications.


  • Life sciences
  • Pharmaceuticals
  • Biologics
  • Synthetic biology and industrial biotechnology
  • Patent law
  • Licensing and technology transfer transactions
  • Intellectual property litigation



  • Represented Jiangsu Hengrui Medicine Co. Ltd. in out-licensing of its JAK inhibitor drug, SHR0302 to Arcutis, Inc.
  • Represented CSPC Pharmaceutical Group Limited in multiple licensing transactions with U.S. universities and companies to obtain rights to various cancer therapeutics.
  • Represented Shenzhen Beike Biotechnology Co., Ltd., a leading Chinese cell-based therapy company, in a license agreement with Altor BioScience Corporation (Altor), a U.S.-based developer of novel cancer immunotherapies, to develop and commercialize Altor’s proprietary Interleukin-15 based superagonist complex, in China.
  • Represented public company Huapont Life Sciences Co. Ltd. in a number of strategic investment and licensing deals in the U.S.
  • Represented HitGen Ltd., leader in DNA-encoded library technology in China, in a number of transactions with U.S. pharmaceutical companies including Merck, Pfizer, Monsanto, BASF, Amgen, Sanofi, Takeda, Shire, Boehringer, Celgene, etc.
  • Represented Shanghai Jingfeng Pharmaceutical Company in a licensing deal with Carbylan Biosurgery, Inc. where Jingfeng acquired rights to Carbylan's Hydros-TA technology and related products for the Greater China territory.
  • Represented Adagene (Suzhou) Limited in a number of licensing and joint development deals with various foreign biotech and pharmaceutical companies.
  • Represented Innovent Biologics (Suzhou) Co., Ltd. in negotiating and finalizing a number of licensing agreements with various foreign biotech and pharmaceutical companies.
  • Represented Zhongyuan Union Cell & Gene in its $300mm acquisition of OriGene Technologies, Inc., a U.S. gene and antibody product company.

Recognition & Leadership

  • Listed, IAM Strategy 300 Global Leaders – The World’s Leading IP Strategists, 2021-2022
  • Listed, IAM magazine, "IAM Patent 1000," Prosecution, 2020-2022
  • Listed, IAM Strategy 300 – The World’s Leading IP Strategists, 2016-2021
  • Listed, LMG Life Sciences, "Life Science Star," 2017-2021
  • Listed, Law360, "Top Attorneys Under 40 - Life Sciences," 2019
  • Member, Bayhelix, Chinese Business Leaders in Life Sciences
  • Member, American Bar Association
  • Member, Boston Bar Association
  • Member, Boston Patent Law Association
  • Member, Women Entrepreneurs in Science and Technology
  • Member, Genetics Society of America
  • Member, American Association of the Advancement of Science
  • Member, The Sigma Xi Scientific Research Honor Society


  • J.D., cum laude, Suffolk University Law School
    • International Law Concentration with Distinction
  • Ph.D., Biology, Massachusetts Institute of Technology
    • MIT Presidential Fellow
    • Keck Graduate Fellow
  • B.S., summa cum laude, Peking University
  • Massachusetts
  • U.S. Patent and Trademark Office
  • Chinese (Mandarin), Native